News

Cancer Treatment Centers of America Phoenix, has achieved Magnet recognition by the American Nurses Credentialing Center.

In an interview with Targeted Oncology, Jorge Nieva, MD, provided a recap of the recent ODAC meeting and explained his stance against further research for frontline sintilimab plus chemotherapy for the treatment of patients with nonsquamous NSCLC.

Pancreatic tumor responses to sotorasib in CodeBreak 100 have significantly surpassed the 16% response rate achieved with FDA-approved therapies.

In the largest study of bone marrow-derived macrophages in post hematopoietic stem cell transplantation patients with a hematologic malignancy, results showed that donor derived cells from the myeloablative transplants accounted for 4.1-25% of microglial cells.

In an interview with Targeted Oncology, Lee Schwartzberg, MD, further discusses the findings of KEYNOTE-522 and pembrolizumab in patients with triple negative breast cancer.

Stephanie Lee, MD, MPH, discusses the effectiveness of ruxolitinib within various settings for patients with chronic graft-versus-host disease.

An application for FDA approval has been submitted for poziotinib as a potential treatment for patients with non–small cell lung cancer harboring HER2 exon 20 insertion mutations.

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

Peter Martin, MD, discusses questions asked in regards to patient populations in a real-world study of treatment patterns and outcomes of mantle cell lymphoma.

The FDA’s Oncologic Drug Advisory Committee has voted against approval of the biologics license application for sintilimab plus pemetrexed and platinum-based chemotherapy for the treatment of nonsquamous non–small cell lung cancer without further clinical trial research.

In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.

In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.

In an interview with Targeted Oncology™, Ming Zhao, MD, discusses the results of the FOHAIC-1 clinical trial and how it compares to HAIC-FO for the treatment of HCC.

In an interview with Targeted Oncology, James Brugarolas, MD, PhD discussed promising updated survival data in metastatic renal cell carcinoma and investigational biomarkers to further advanced the field.

The novel oncolytic adenovirus, VCN-01 has been granted FDA orphan drug designation for retinoblastoma and will soon be investigated in a phase 2/3 clinical trial.

In an interview with Targeted Oncology, Toufic Kachaamy, MD, discussed in detail the role of the gastroenterology community in staging, diagnosing, and managing gastrointestinal malignancies.

Statistically significant improvement in progression-free survival has been shown with selinexor in patients with advanced or recurrent endometrial cancer, including those with wild-type p53.

With custom QCDR measures identified by physician leaders in The US Oncology Network, McKesson has been received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System as a registry.

Srdan Verstovsek, MD, PhD, discusses the main reasons for his study on the use of rusfertide in patients with polycythemia vera.

Findings around trametinib as treatment of patients with an ovarian cancer subtype represent a major advance in the treatment of women with this rare ovarian and peritoneal cancer subtype, according to David Gershenson, MD.

After treatment with SurVaxM in patients with newly diagnosed glioblastoma significantly improved survival, investigators are continuing the evaluation of the agent in a phase 2b clinical trial.

In an interview with Targeted Oncology, Christopher Melani, MD, discussed the ongoing ViPOR study exploring a Bruton’s tyrosine kinase inhibitor and BCL2 inhibitor, and NF-κB survival pathway activating combination.

In an interview with Targeted Oncology, Michael A. Postow, MD, summarized the treatment landscape, provided takeaways from the most recent additions, and discussed other targets for metastatic melanoma.

In an interview with Targeted Oncology, Casey M. Cosgrove, MD, discussed the current state of biomarkers for patients with endometrial cancer and how they can be used for prognostic purposes.

AHN is utilizing a minimally-invasive surgery technique to provide better care to patients with cancer.

In its new Sunnyvale, Texas location, GenesisCare offers comprehensive patient-centered services for patients with breast cancer.

Based on data from phase 3 ECHELON-1 brentuximab vedotin in combination with chemotherapy extends survival in patients with advanced classical Hodgkin lymphoma.

Concomitant mutations, and high PD-L1 expression may be associated with an unfavorable clinical response to second-generation tyrosine kinase inhibitors in patients with ALK-rearrange non–small cell lung cancer.

Tanios S. Bekaii-Saab, MD, FACP, Richard S. Finn, MD, and William P. Harris, MD, highlight advances in research and clinical treatment of hepatocellular carcinoma over the past 10 years.

The FDA kicked off 2022 with an approval for the treatment of select patients with uveal melanoma. Here's a look back at all the FDA happenings from January 2022.